Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells

Clinical studies evaluating targeted BRAFV600E inhibitors in advanced thyroid cancer patients are currently underway. Vemurafenib (BRAFV600E inhibitor) monotherapy has shown promising results thus far, although development of resistance is a clinical challenge. The objective of this study was to cha...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Hanly, Elyse K., Tuli, Neha Y., Bednarczyk, Robert B., Suriano, Robert, Geliebter, Jan, Moscatello, Augustine L., Darzynkiewicz, Zbigniew, Tiwari, Raj K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2015
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4890996/
https://ncbi.nlm.nih.gov/pubmed/26735176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6779
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi